Page 1 of 1

Ø 4B TOOL: UTI Guidelines Form

Tools and Resources

Purpose: Urinary tract infection (UTI) treatment guidelines. Gives background, local microbiology data, and suggested empiric regimens.

Source: F. Palmieri, Bronx-Lebanon Hospital.

Instructions: Review and adapt as appropriate.

Background

  • Escherichia coli constituted 91 percent of community-acquired urinary isolates in the past year in BLHC.
  • Bacterial resistance to sulfamethoxazole/trimethoprim (SMZ/TMP) and fluoroquinolones has increased.
  • Urine culture and susceptibility (C & S) tests are strongly recommended for any therapy changes.
  • Modify therapy according to BLHC UTI guidelines.
  • Do not use SMZ/TMP as empiric therapy or ciprofloxacin as initial therapy due to high resistance to E. coli.

% Sensitive Urinary Isolates, Community Acquired (2010)

E. ColiAntibiotics
45Ampicillin/sulbactam
75Amoxicillin/clavulanate
92Ceftriaxone
78Cefazolin
74Ciprofloxacin
87Cefuroxime
94Nitrofurantoin
95Piperacillin/tazobactam
63Sulfamethoxazole/trimethoprim
88Gentamicin
39Ampicillin

Guideline Recommendations

Step 1: Urinalysis

  • Urinalysis (UA).
  • Urine micro.
  • Urine culture:
    • Before antibiotics are started.
    • For ED patients.
    • Inpatients with UTIs.
    • All patients with suspected pyelonephritis.

Step 2: Empiric Antibiotics

Step 3: Pathogen-Directed Therapy

  • With culture and susceptibility results, change antibiotic to pathogen-specific agent.
  • Follow up on all discharged patients to provide appropriate therapy based on culture and sensitivity results.
  • SMZ/TMP can be used at this point as dictated by the C & S results.
  • Reserve fluoroquinolones for pyelonephritis and major systemic infections due to resistance development.

Step 4: Duration

  • As important as the therapy itself.
  • Excessive use can lead to:
    • Adverse reactions.
    • Increased antimicrobial resistance.
  • Refer to table for specific duration recommendations.

Step 5: Epidemiologic Surveillance

  • With time and selective pressure, resistance patterns will change.
  • At least once a year, susceptibility patterns will be reassessed and the need to change treatment recommendations evaluated.

Asymptomatic Bacteriuria

  • Asymptomatic bacteriuria is defined as isolation of a specific quantitative count of bacteria in an appropriately collected urine specimen from an individual without sign or symptoms of a urinary tract infection.
  • Avoiding treatment of asymptomatic bacteriuria is important for reducing the development of antibiotic resistance.
  • Treatment of asymptomatic bacteriuria is not appropriate for: women (premenopausal, nonpregnant), diabetics, elderly people, nursing home residents, or patients with spinal cord injury or indwelling urethral catheters.
  • Treatment of asymptomatic bacteriuria is appropriate for pregnant women and for patients undergoing urologic procedures in which mucosal bleeding is expected.

Empiric Therapy Regimen

Acute Uncomplicated Cystitis
Antibiotic RecommendationsCautionDurationPossible Side Effects (selected)
Nitrofurantoin (Macrobid) 100 mg twice dailyDo not use if CrCl <60.

Do not use for elderly patient >65 years old.

Do not use during pregnancy at term (38 to 42 weeks gestation).

Caution in cholestatic jaundice and hepatic dysfunction.
5 daysGI intolerance; Lupus-like reactions; rash

Rare: peripheral neuropathy; trigeminal neuralgia pulmonary reactions; hepatitis; hemolytic anemia in G6PD deficiency
Cefuroxime 250 mg oral q12hAvoid in penicillin allergy.

If CrCl <10mL/min, administer once daily.
7 daysAnaphylaxis (PCN allergic); diarrhea; other super infections; eosinophilia; positive Coombs test; interstitial nephritis; hemolytic anemia
Cefpodoxime 100 mg oral q12hAvoid in penicillin allergy.

If CrCl <30mL/min, administer once daily.
7 daysAs above
Ciprofloxacin 250 mg oral q12h—3rd line therapy due to resistance. If selected, urine culture with followup is recommended.If CrCl <30mL/min, administer once daily.5 daysC. difficile colitis; QTc prolongation; nephritis; tendon rupture; neuropathy
Acute Uncomplicated Pyelonephritis
Antibiotic RecommendationsCautionDurationPossible Side Effects (selected)
Initial Therapy
Ceftriaxone 1 g IV/IM 1st doseAvoid in serious, type-I PCN allergyInitial doseAs above for cefuroxime plus pseudocholelithiasis
Gentamicin IV 3 mg/kg x1 doseNo adjustment for initial dose needed for renal failureInitial doseRenal function
Followup Therapy—Tailor Therapy to Culture and Sensitivity Report; Otherwise:
Ciprofloxacin 500 mg oral q12hAs above7 to 14 daysAs above
Cefuroxime 250 mg oral q12hAs above7 to 14 daysAs above
Cefpodoxime 200 mg oral q12hAs above7 to 14 daysAs above

References

1. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women. A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011:52(5):e103-20. Review.

2. Nicolle LE, Bradley S, Colgan R, et al Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005;40:643-54.

Return to Question 4

Current as of September 2012
Internet Citation: Ø 4B TOOL: UTI Guidelines Form: Tools and Resources. September 2012. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/professionals/quality-patient-safety/patient-safety-resources/resources/cdifftoolkit/cdiffl2tools4b.html